About Ventric Health
Ventric Health is a Pasadena-based medical technology company focused on improving cardiovascular health by empowering earlier detection of heart failure, especially in primary care settings. It develops non-invasive diagnostic solutions that help clinicians find and intervene in heart disease sooner.
Ventric Health’s mission is to create non-invasive heart diagnostic solutions that quickly deliver actionable insights to reduce care costs and improve patient lives, particularly for value-based care organizations and healthcare teams.
The company aims to bring non-invasive cardiovascular testing to everyone — expanding diagnosis beyond traditional environments and diagnosing patients earlier to improve clinical outcomes.
Ventric was founded in 2014 to commercialize technology developed in the laboratory of the California Institute of Technology based on breakthrough cardiovascular research conducted by Professor Mory Gharib and his postdoctoral fellows Niema Pahlevan and Derek Rinderknecht.
Vivio® — Heart Failure Diagnostic System
Vivio® is Ventric Health’s flagship non-invasive medical device designed to detect elevated left ventricular end-diastolic pressure (LVEDP), the clinical hallmark of heart failure. It can be used in primary care and home health settings.
The Vivio System uses patented advanced hemodynamic algorithms and data measurements to non-invasively indicate elevated LVEDP in under five minutes, giving clinicians real-time results during a standard visit.
Unlike catheterization or echocardiograms, Vivio’s non-invasive design improves accessibility, speed, and ease thus improving patient experience. Because Vivio directly identifies elevated LVEDP it provides a more sensitive measurement and conclusive diagnosis than any other tool available to clinicians in the outpatient setting.
Clinicians can perform the test in under five minutes with results available immediately.
Vivio® has demonstrated high sensitivity and specificity to elevated filling pressures and has been validated in clinical studies for effective early detection of heart failure.
Yes. Vivio® received 510(k) clearance from the U.S. Food and Drug Administration to indicate elevated filling pressure in October 2023 — making it the only FDA-cleared non-invasive medical device of its kind.
Clinical Impact & Use Cases
Ventric Health was designed to serve primarily clinicians and care teams responsible for at-risk populations, including primary care providers and value-based care organizations looking to identify and manage heart failure earlier within at-risk patient populations.
Heart failure symptoms are often overlooked in routine assessments, and traditional diagnostics can be delayed or inconclusive; catching elevated filling pressure early helps clinicians intervene sooner, improve outcomes and reduce healthcare costs.
Yes — because Vivio® is mobile and non-invasive, trained clinicians can bring the device directly to patients in home health or community settings, overcoming barriers like transportation and access.
The Resources Hub includes clinical articles and validation studies showing Vivio’s effectiveness in different care settings.
Outcomes & Benefits
Practices using Vivio® have reported increased early diagnoses especially in the primary care setting, better guideline-directed therapy initiation, decreased hospitalizations and ER visits, and improved medication compliance.
Clinical feedback indicates high patient preference for Vivio compared to traditional diagnostics and ease of administration. Patients appreciate providers’ proactive approach to their heart health.
By enabling earlier detection and treatment of heart failure risk, Vivio® helps reduce avoidable hospitalizations, emergency department visits, and downstream costs associated with late-stage disease. A positive Vivio test – coupled with appropriate chart documentation – allows for the submission of ICD-10 I50.1 which continues to map to HCC 226 under the current CMS RAF-HCC v28 model.
Partnerships & Implementation
Implementation is very straightforward. Care teams interested in Vivio® can request a demo via the Ventric Health website to explore practical implementation approaches within their clinical workflow.
Yes. A key part of the implementation process is to ensure physicians and clinical support staff fully understand how Vivio® works, choose the most effective workflow, and can successfully deploy the appropriate treatment processes.
General Website / Legal Questions
The site is intended for users 18 or older and is meant for general information and legitimate business use in connection with Ventric Health’s services.
The Terms of Use restrict reproduction, distribution, and derivative works unless explicitly permitted by the company.
No. The content on the Ventric Health website is for informational purposes only and does not replace professional medical advice.
The site is intended for healthcare professionals, organizations, partners, and individuals seeking information about Ventric Health’s technology and mission.
For Clinicians & Care Teams
Clinical Need & Value
Vivio® System
Workflow & Practice Impact
For Value-Based Care Organizations & Health Systems
Outcomes & Cost Management
Scalability & Deployment
For Home Health & Community-Based Care Teams
Yes — because Vivio® is mobile and non-invasive, trained clinicians can bring the device directly to patients in home health or community settings, overcoming barriers like transportation and access.
Yes. Vivio® is mobile and non-invasive, making it suitable for home visits, community clinics, and post-acute care settings.
By bringing advanced cardiovascular assessment directly to the patient, Vivio® reduces barriers such as access to transportation, scheduling delays, and referral bottlenecks.
For Patients & Caregivers
Understanding the Test
Benefits to Patients
For Partners, Investors & Industry Stakeholders
Ventric Health focuses on non-invasive, point-of-care solutions that extend advanced cardiovascular insights into primary care and community settings where most patients are first seen. Ventric Health’s Vivio System is the first and only FDA-cleared medical device available that can non-invasively identify elevated LVEDP – the clinical hallmark of heart failure.
The underdiagnosis and delayed diagnosis of heart failure, which contributes to patient suffering, poor outcomes and high healthcare costs.
To make advanced, non-invasive cardiovascular assessment accessible to everyone, enabling earlier intervention and better outcomes across the care continuum.
